Key terms
About ADTX
Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Richmond, VA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ADTX news
Apr 04
5:13pm ET
Aditxt, Inc. Announces Strategic Acquisition of Appili Therapeutics
Apr 02
8:39am ET
Aditxt in pact to acquire Appili Therapeutics for 5.6c per share
Apr 02
7:50am ET
Appili Therapeutics signs definitive agreement to be acquired by Aditxt
Feb 21
4:49pm ET
Aditxt Secures Dawson James for M&A Advisory Role
Feb 16
4:44pm ET
Aditxt, Inc. CEO’s $205K Loan to Bolster Company Growth
Feb 15
4:45pm ET
Aditxt, Inc. Faces Defaults and Loan Breaches, Negotiates with Lenders
Feb 10
4:39am ET
Aditxt CEO Provides Short-Term Loan to Bolster Stability
Feb 10
4:39am ET
Aditxt, Inc. Enters New Financial Obligation Impacting Investors
Feb 07
4:58am ET
Aditxt, Inc. Restructures Debt Post-Merger with Evofem
Jan 18
4:33pm ET
Aditxt files to sell 3.785M shares of common stock for holders
Jan 08
9:00am ET
ADiTx Therapeutics trading resumes
Jan 08
8:25am ET
ADiTx Therapeutics trading halted, news pending
No recent press releases are available for ADTX
ADTX Financials
Key terms
Ad Feedback
ADTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ADTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range